Keywords

Bone cancer

Breast Cancer

General Oncology

Gynecological Cancers

Head and neck cancer

Lung Cancer

Radiation Oncology

Dual-targeting CAR-T cells and bispecific antibodies for multiple myeloma

Authors:

Quande Lin

The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China

Correspondence to Author: Quande Lin

Abstract:

During the past few years, patients with relapsed or refractory multiple myeloma (RRMM) have been treated using bispecific antibodies (BsAbs) and dual-targeted chimeric antigen receptor T (CAR T) cells, as more and more patients were not adequately helped by at least three prior rounds of therapy. The most common combos are GPRC5D/CD3 and BCMA/CD3. According to clinical results, patients are more likely to experience stronger and longer-lasting responses. Here, we present the most recent information on BsAbs that target BCMA/CD3, GPRC5D/CD3, and BCMA/CD19 CAR T cells, as presented at the ASCO annual meeting in 2023.

Keywords:

Multiple myeloma, Bispecific antibody, CAR T, Clinical trial

Citation:

Quande Lin. Dual-targeting CAR-T cells and bispecific antibodies for multiple myeloma. World Journal of Medical Oncology 2023

Journal Info

  • Journal Name: World Journal of Medical Oncology
  • Impact Factor: 2.709**
  • ISSN: 2766-6077
  • DOI: 10.52338/wjoncgy
  • Short Name: WJMOY
  • Acceptance rate: 55%
  • Volume: 6 (2024)
  • Submission to acceptance: 25 days
  • Acceptance to publication: 10 days

INDEXING

  • Crossref indexed journal impact factor of 2.980**
  • Publons indexed journal impact factor of 3.90**
  • Pubmed-indexed journal impact factor of 5.2**
  • International Scientific Indexing (ISI)-indexed journal impact factor of 2.980**
  • Eurasian Scientific Journal Index (ESJI) index journal impact factor of 2.980**
  • Semantic Scholar indexed journal impact factor of 2.980**
  • Cosmos indexed journal impact factor of 3.981**

OUR PUBLICATION BENEFITS

  • International Reach
  • Peer Review
  • Rapid Publication
  • Open Access
  • High Visibility